Susan Kim, MD

Susan Kim, MD, MMSc, is a Pediatric Rheumatologist and Clinical Professor of Pediatrics at UCSF Medical School, who sees patients in the Rheumatology Clinics at UCSF Benioff Children's Hospital’s San Francisco and Oakland sites.

Dr. Kim specializes in caring for all children and adolescents with inflammatory rheumatic diseases, including Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosis, Vasculitis, Scleroderma and Autoinflammatory conditions, with a particular focus in Juvenile Dermatomyositis (JDM).

Her research focus is on JDM, where she is working to improve clinical management, care and outcomes of patients by working to standardize assessments and treatment approaches. She is also working with laboratory and translational researchers to expand our knowledge in this rare condition. As part of this work, she directs the combined Rheumatology Dermatology Clinic at UCSF that seeks to improve the care of children with autoimmune skin diseases like JDM.

Dr. Kim received her medical degree from SUNY Downstate, and master’s degree from Harvard Medical School, completed a residency in pediatrics at Columbia Presbyterian Hospital in NYC, completed a fellowship in pediatric rheumatology at Boston Children’s Hospital and worked as an attending physician in pediatric rheumatology at Boston Children’s Hospital until 2016 before moving to the Bay Area.

Dr. Kim is a member of the American College of Rheumatology and the Childhood Arthritis & Rheumatology Research Alliance (CARRA), and the Pediatric Dermatology Research Alliancce (PeDRA). She serves as the elected Chair for the Juvenile Dermatomyositis research committee of CARRA. She also serves as a member of the scientific advisory committee for the International Myositis Assessment & Clinical Studies Group (IMACS) and Medical Advisory Board for CureJM.
Publications
  1. Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry.
  2. Multi-Modal Single-Cell Sequencing Identifies Cellular Immunophenotypes Associated With Juvenile Dermatomyositis Disease Activity.
  3. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease.
  4. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease.
  5. Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.
  6. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
  7. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
  8. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
  9. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
  10. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa.
  11. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa.
  12. Access to Care and Diagnostic Delays in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
  13. Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America.
  14. Clinical characteristics and management of clinically amyopathic juvenile dermatomyositis across four academic centers.
  15. Parent Perspectives on Addressing Emotional Health for Children and Young Adults With Juvenile Myositis.
  16. Investigating genetic drivers of dermatomyositis pathogenesis using meta-analysis.
  17. Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study.
  18. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis.
  19. Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry.
  20. Advances Toward Precision Medicine in Juvenile Dermatomyositis.
  21. Gene Expression Meta-Analysis Reveals Concordance in Gene Activation, Pathway, and Cell-Type Enrichment in Dermatomyositis Target Tissues.
  22. Association of Short-Term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
  23. Comparing the importance of quality measurement themes in juvenile idiopathic inflammatory myositis between patients and families and healthcare professionals.
  24. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.
  25. School Self-Concept in Adolescents With Chronic Pain.
  26. Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.
  27. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
  28. Predicting Coronary Artery Aneurysms in Kawasaki Disease at a North American Center: An Assessment of Baseline z Scores.
  29. Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.
  30. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease.
  31. American Journal of Surgical Pathology
  32. Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash.
  33. Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study.
  34. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
  35. Next-Generation Sequencing Reveals Restriction and Clonotypic Expansion of Treg Cells in Juvenile Idiopathic Arthritis.
  36. Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences.
  37. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
  38. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
  39. Are panoramic radiographs predictive of temporomandibular joint synovitis in children with juvenile idiopathic arthritis?
  40. Physical findings associated with active temporomandibular joint inflammation in children with juvenile idiopathic arthritis.
  41. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
  42. Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies.
  43. Differentiating arthritic from myofascial pain in children with juvenile idiopathic arthritis: preliminary report.
  44. Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease.
  45. Multiple juvenile idiopathic arthritis subtypes demonstrate proinflammatory IgG glycosylation.
  46. Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions.
  47. Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis.
  48. Assessing the performance of the Birmingham Vasculitis Activity Score at diagnosis for children with antineutrophil cytoplasmic antibody-associated vasculitis in A Registry for Childhood Vasculitis (ARChiVe).
  49. Magnetic resonance imaging of temporomandibular joints in children with arthritis.
  50. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference.
  51. Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood.
  52. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment.
  53. NOD2-associated diseases: Bridging innate immunity and autoinflammation.
  54. MRI findings of juvenile psoriatic arthritis.
  55. Chronic minocycline-induced autoimmunity in children.
  56. Update on pediatric vasculitis.
  57. Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase.
  58. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.